These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25358680)

  • 21. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frontotemporal Lobar Degeneration.
    Premi E; Padovani A; Borroni B
    Adv Exp Med Biol; 2012; 724():114-27. PubMed ID: 22411238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Tau and Its Ligands in PET Imaging.
    Harada R; Okamura N; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Biomolecules; 2016 Jan; 6(1):7. PubMed ID: 26751494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid tau in frontotemporal lobar degeneration: clinical, neuroimaging, and prognostic correlates.
    Borroni B; Cerini C; Archetti S; Premi E; Cosseddu M; Ferrari M; Bellelli G; Gasparotti R; Caimi L; Di Luca M; Padovani A
    J Alzheimers Dis; 2011; 23(3):505-12. PubMed ID: 21098973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau imaging in neurodegenerative diseases.
    Dani M; Brooks DJ; Edison P
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1139-50. PubMed ID: 26572762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Brain functional imaging of frontotemporal lobar degeneration].
    Nakano S; Matsuda H
    Brain Nerve; 2009 Nov; 61(11):1275-84. PubMed ID: 19938684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.
    Maia LF; Kaeser SA; Reichwald J; Hruscha M; Martus P; Staufenbiel M; Jucker M
    Sci Transl Med; 2013 Jul; 5(194):194re2. PubMed ID: 23863834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.
    Snowden JS; Thompson JC; Stopford CL; Richardson AM; Gerhard A; Neary D; Mann DM
    Brain; 2011 Sep; 134(Pt 9):2478-92. PubMed ID: 21840888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration.
    van Eersel J; Stevens CH; Przybyla M; Gladbach A; Stefanoska K; Chan CK; Ong WY; Hodges JR; Sutherland GT; Kril JJ; Abramowski D; Staufenbiel M; Halliday GM; Ittner LM
    Neuropathol Appl Neurobiol; 2015 Dec; 41(7):906-25. PubMed ID: 25763777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative approaches to amyloid imaging.
    Villemagne VL; O'Keefe G; Mulligan RS; Rowe CC
    Methods Mol Biol; 2011; 680():201-25. PubMed ID: 21153383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging beta-amyloid burden in aging and dementia.
    Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
    Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Untangling tau imaging.
    Villemagne VL; Okamura N; Rowe CC
    Alzheimers Dement (Amst); 2016; 4():39-42. PubMed ID: 27489878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.